New Therapeutic Strategy Against Preeclampsia

The aim of this biobank is to setup a collection of maternal plasma and serum from patients with preeclampsia and patients with normal pregnancy. Assays of circulating angiogenic and anti-angiogenic factors (free and total forms) will be carried out on these serum and plasma at the hormonology laboratory in Cochin hospital (Paris, France) These results will make it possible to optimize and validate the development of extracorporeal sFlt-1 purification techniques. Preeclampsia is a very heterogeneous disease in its clinical presentation, our hypothesis is that this heterogeneity corresponds to different profiles of angiogenic balance disturbance. Not all patients are likely to have the same expected benefit from extracorporeal clearance of sFlt-1. The objective is to assess the overall angiogenic balance on a large number of patients in order to determine which profile best corresponds to the indication for apheresis. A prospective non-interventional study will be initiated to collect maternal blood samples during normal pregnancies and during pregnancies complicated by preeclampsia (Port-Royal Maternity, Cochin APHP). Blood samples will be collected after collection of written informed consent from 50 patients with preeclampsia and 50 patients without hypertensive disease. * Between 20WG and 23WG+6D : 10 patients with PE and 10 patients with NP * Between 24WG and 27WG+6D : 10 patients with PE and 10 patients with NP * Between 28WG and 31WG+6D : 10 patients with PE and 10 patients with NP * Between 32WG and 35WG+6D : 10 patients with PE and 10 patients with NP * Between 36WG and 40WG+6D : 10 patients with PE and 10 patients with NP Inclusion of the patients will be performed through the Cochin maternal/neonatal investigation center.